Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Sintilimab

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hutchmed & Innovent Win NMPA OK for Elunate+ Tyvyt in Carcinoma
    Hutchmed & Innovent Win NMPA OK for Elunate+ Tyvyt in Carcinoma

    21 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/21/3299110/0/en/hutchmed-and-innovent-jointly-announce-nmpa-approval-for-elunate-fruquintinib-in-combination-with-tyvyt-sintilimab-injection-for-the-treatment-of-patients-with-locally-advanced-or-.html

    GLOBENEWSWIRE
    21 May 2026
    Share Share
    NMPA OKs Innovent's TABOSUN: China's 1st Domestic Anti-CTLA-4 mAb
    NMPA OKs Innovent's TABOSUN: China's 1st Domestic Anti-CTLA-4 mAb

    25 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/chinas-first-domestic-anti-ctla-4-monoclonal-antibody-innovents-tabosun-ipilimumab-n01-injection-received-nmpa-approval-302649444.html

    PR NEWSWIRE BIO
    25 Dec 2025
    Share Share
    Hutchmed Expands Its NRDL Coverage, Joins First Commercial List
    Hutchmed Expands Its NRDL Coverage, Joins First Commercial List

    07 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201158/0/en/HUTCHMED-Announces-Expanded-Coverage-on-National-Reimbursement-Drug-List-and-Inclusion-in-the-First-Commercial-Insurance-Drug-List-in-China.html

    GLOBENEWSWIRE
    07 Dec 2025
    Share Share
    Hutchison China Meditech Showcases Clinical Data At 2025 ESMO
    Hutchison China Meditech Showcases Clinical Data At 2025 ESMO

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/27/3195434/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-2025-ESMO-Asia-Congress-and-the-2025-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    HUTCHMED to Present FRUSICA-2 Trial Data at ESMO 2025
    HUTCHMED to Present FRUSICA-2 Trial Data at ESMO 2025

    13 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/13/3165267/0/en/HUTCHMED-Highlights-FRUSICA-2-Registration-Trial-Data-to-be-Presented-at-the-2025-ESMO-Congress.html

    GLOBENEWSWIRE
    13 Oct 2025
    Share Share
    Hutchmed Showcases Clinical Data At Esmo Congress 2025
    Hutchmed Showcases Clinical Data At Esmo Congress 2025

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.